

Health Technology Assessment of Hospital Medicines in Denmark: A Review of DMC Decisions (2017-2022)

Authors: Viollet J¹, O'Leary E¹, Lauppe R¹, Oldsberg L¹, Rosenzweig M²
Affiliation: ¹Quantify Research, Stockholm, Sweden, ²Quantify Research, Copenhagen, Denmark

Objectives

- The Danish Medical Council (DMC) assesses hospital drugs and publishes recommendations on use. The possible outcomes are:
 - Recommended
 - Partially recommended
 - Not recommended
 - Directly included in treatment guidelines
- Objective: to describe the DMC evaluations and decisions made since its inception and to investigate grounds for negative recommendations


Methods

- Data from all decisions available on the DMC website on 1st June 2022 was collected
- Variables extracted:
 - Product and indication specifics: product name, substance name, manufacturer name, whether it was a combination treatment
 - DMC subject committee
 - Date of preliminary application and date of decision
 - Case processing time
 - Decision outcome
- For products that were not recommended: further information was collected about the grounds for the decision
 - The reasons were coded as four categories for analysis: unacceptable side effects, unacceptably high price, uncertainty in the health economic evaluation, and worse clinical effect than current treatment (more than 1 can be applicable)


Results

- 178 decisions identified with different outcomes
 - Reimbursement: 51% recommended, 17% partially recommended and 32% were not recommended
 - 98% underwent a health professional assessment focusing on the value of the drug
 - All decisions but one reassessment included an economic analysis (cost analysis and budget impact analysis)
 - Average reported processing time: around 112 days, with no statistically significant difference based on decision outcome
 - Only 8 were assessed according to the updated 2021 DMC guidelines (4 applications included cost-effectiveness analyses and 4 cost-minimisation analyses)
 - Average reported processing time: 139 days


Oncology was the therapy area most assessed



Oncology subject committees were the most used



Price was the most cited challenge



Conclusions

- The DMC process takes into account multiple dimensions of value
- Key criteria for obtaining a recommendation: health benefit and price